EGFR and glioblastoma: Moreover, a phase II clinical trial involving patients with recurrent glioblastomas exhibiting EGFR amplification revealed that lncRNA RP11.770J1.4 is linked to the response to the combination of Depatux‐M and TMZ (HR 0.587, p = 0.050 and HR 0.322).58